- Home
- VLGEA vs CRMD Comparison
VLGEA vs CRMD Comparison
Compare VLGEA & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VLGEA | CRMD |
|---|---|---|
| Founded | 1937 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 596.9M | 618.2M |
| IPO Year | 1994 | 2009 |
Fundamental Metrics
Financial Performance| Metric | VLGEA | CRMD |
|---|---|---|
| Price | $44.73 | $7.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $14.83 |
| AVG Volume (30 Days) | 36.3K | ★ 893.0K |
| Earning Date | 06-02-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.37% | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | N/A | ★ 2.04 |
| Revenue | ★ $1,612,015,000.00 | $311,709,000.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.31 | ★ $3.88 |
| Revenue Growth | 0.46 | ★ 617.03 |
| 52 Week Low | $30.08 | $6.13 |
| 52 Week High | $45.12 | $17.43 |
Technical Indicators
Market Signals| Indicator | VLGEA | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 62.65 | 60.22 |
| Support Level | $40.30 | $7.05 |
| Resistance Level | $45.12 | $8.53 |
| Average True Range (ATR) | 1.04 | 0.29 |
| MACD | 0.12 | 0.03 |
| Stochastic Oscillator | 98.10 | 75.00 |
Price Performance
Historical ComparisonAbout VLGEA Village Super Market Inc.
Village Super Market Inc operates a chain of ShopRite supermarkets, a few of which are in northern New Jersey, southern New Jersey, Maryland, and in northeastern Pennsylvania. The company is a member of Wakefern Food Corporation (Wakefern), a retailer-owned food cooperative and owner of the ShopRite name. It consists of one operating segment, the retail sale of food and nonfood products.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.